BCAB - BioAtla Inc. (BCAB) Q1 2024 Earnings Call Transcript
2024-05-14 20:35:23 ET
BioAtla, Inc. (BCAB)
Q1 2024 Earnings Conference Call
May 14, 2024 4:30 PM ET
Company Participants
Bruce Mackle – LifeSci Advisors
Jay Short – Chairman, Chief Executive Officer and Co-Founder
Eric Sievers – Chief Medical Officer
Sheri Lydick – Chief Commercial Officer
Richard Waldron – Chief Financial Officer
Conference Call Participants
Brian Cheng – JPMorgan
Dev Prasad – Jefferies
Kaveri Pohlman – BTIG
Arthur He – H.C. Wainwright
Tony Butler – EF Hutton
Presentation
Operator
Greetings and welcome to the BioAtla First Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Bruce Mackle, with LifeSci Advisors. Thank you, Bruce. You may begin.
Bruce Mackle
Thank you, operator, and good afternoon, everyone. With me today on the phone from BioAtla are Dr. Jay Short, Chairman, CEO and Co-Founder; Dr. Eric Sievers, Chief Medical Officer; Sheri Lydick, Chief Commercial Officer; and Richard Waldron, Chief Financial Officer. Following today’s call the team will participate in a short Q&A. Earlier this afternoon, BioAtla released financial results and a business update for the first quarter ended March 31, 2024. A copy of that press release and corporate presentation are available on the company’s website.
Before we begin, I’d like to remind everyone that statements made during this conference call will include forward-looking statements, including, but not limited to, statements regarding BioAtla’s business plans and prospects and whether it’s clinical trials will support registration, plans to form collaborations and other strategic partnerships for selected assets; achievements of milestones, results, conduct, progress and timing of its research and development programs in clinical trials; expectations with respect to enrollment and dosing in its clinical trials, plans and expectations regarding future data updates, clinical trials, regulatory meetings and regulatory submissions, the potential regulatory approval path for its product candidates; expectations about the sufficiency of its cash and cash equivalents to fund operations and expectations regarding R&D expenses and cash burn....
BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript